BridgeBio rises after study shows drug improving growth in children with dwarfism
12/02/2026 14:06
** Shares of BridgeBio Pharma BBIO.O rise 15.7% to $84.83 premarket ** Co says its experimental therapy boosted growth rates in children with a rare genetic disorder that causes dwarfism, according to results from a late-stage study ** Says the oral therapy, infigratinib, improved growth rate by 1.74 cm compared with placebo after 52 weeks in children with achondroplasia, a condition that causes disproportionately short stature ** "We continue to see a clear path for BBIO to rapidly become a 4-product company (from 1 today), all of which have blockbuster potential," says brokerage Evercore ISI ** As of last close, stock up 135.6% in the last 12 months (Reporting by Puyaan Singh) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels